Wednesday, July 2, 2025 7/2/2025

Mechanism of Chemotherapy Induced Microvascular Dysfunction in Cancer Survivors

Award Number: R01HL173549
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

Mechanism of Chemotherapy Induced Microvascular Dysfunction in Cancer Survivors - Project Abstract Every year 255,000 new cases of breast cancer are diagnosed amounting to well over 4,000 deaths occurring per year in U. S alone. With the use of anthracycline-based polychemotherapy (including doxorubicin), the reduction in annual deaths from breast cancer is approximately 38% for women under 40. Systemic Chemotherapy (CTx) plays an important role in the management of these patients; however, most CTx agents have severe adverse consequences on the cardiovascular system. Injury to the heart as a result of exposure to CTx is well established; however, little data exist on the contribution of CTx to endothelial cell dysfunction and the direct effect on mitochondria in the microcirculation. Doxorubicin (DOX), a widely used CTx drug, is known to cause excessive DNA damage, including in the mitochondria where DNA damage increases reactive oxygen species (ROS) production. Mitochondrial dysfunction, induced by mitochondrial DNA (mtDNA) damage, uncouples coronary blood flow from cardiac workload. Excessive mtDNA damage leads to an elevation in cell free (cf) mtDNA which is known to act as a secondary messenger, triggering an inflammatory response in the vascular endothelium. cfmtDNA has been observed in disease models of endothelial dysfunction and correlated with poor clinical outcomes but not investigated on a mechanistic level or in Cardio-Oncology. The restoration of mitochondrial integrity in the coronary microvasculature has proven to be sufficient to restore normal heart function, yet few reports show CTx effect on mitochondrial function, and none have investigated effects in the microvasculature. To date, no studies exist which consider the contribution of mitochondrial function and mtDNA damage on cell survival and physiological endothelial function after CTx in human coronary vessels. We speculate the acute effect of CTx induced mtDNA damage is further amplified by elevation of circulating mtDNA fragments, leading to diminished vascular reactivity. As CTx is known to be more effective at damaging cancerous cells than host and endothelial cells, elevation of mtDNA fragments after effective anticancer therapy is a reasonable expectation. This raises the possibility that CTx-induced endothelial dysfunction may play a key role in development of myocardial pathologies. The focus of this proposal is to define the direct signaling events that mechanistically link CTx to microvascular endothelial damage.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $696,647 )
2025	2025	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Cardiovascular Diseases Research	001	2	6/26/2025	NON-COMPETING CONTINUATION	$69,664
2025	2025	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Cardiovascular Diseases Research	000	2	4/10/2025	NON-COMPETING CONTINUATION	$626,983
														Subtotal = $696,647

Issue Date FY: 2024 ( Subtotal = $693,424 )
2024	2024	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Cardiovascular Diseases Research	001	1	6/10/2024	NEW	$69,343
2024	2024	THE MEDICAL COLLEGE OF WISCONSIN, INC.	8701 WATERTOWN PLANK RD	MILWAUKEE	WI	53226	MILWAUKEE	USA	Cardiovascular Diseases Research	000	1	4/1/2024	NEW	$624,081
														Subtotal = $693,424

Grand Total All Awards = $1,390,071

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanism of Chemotherapy Induced Microvascular Dysfunction in Cancer Survivors

Award Number: R01HL173549

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer